LeonaBio, Inc. (LONA)
$7.94+$0.05 (+0.63%) Today
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 11 | 230,999 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
46 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| PERCEPTIVE ADVISORS LLC | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Fred Callori | Grant or award | Stock Option (Right to Buy) | 2,333 | $0.00 | - | |
| Natalie C. Holles | Grant or award | Stock Option (Right to Buy) | 2,333 | $0.00 | - | |
| Peter B. Silverman | Grant or award | Stock Option (Right to Buy) | 2,333 | $0.00 | - | |
| Michael A. Panzara | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Kelly A. Romano | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Joseph Edelman | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| James A. Johnson | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Barbara Kosacz | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
 Grant Pickering | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Natalie C. Holles | Grant or award | Stock Option (Right to Buy) | 56,000 | $0.00 | - | |
| Peter B. Silverman | Grant or award | Stock Option (Right to Buy) | 56,000 | $0.00 | - | |
| Fred Callori | Grant or award | Stock Option (Right to Buy) | 56,000 | $0.00 | - | |
| Michael A. Panzara | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Kevin Church - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Barbara Kosacz | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Grant Pickering | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Kelly A. Romano | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| James A. Johnson | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Joseph Edelman | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Martin Javier San - Officer | Grant or award | Stock Option (Right to Buy) | 350,000 | $0.00 | - | |
| John M. Fluke Jr. | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Mark Worthington - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Robert Renninger - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Mark James Litton - Officer | Grant or award | Stock Option (Right to Buy) | 750,000 | $0.00 | - | |
| Mark James Litton - Officer | Option exercise | Common Stock | 22,254 | $0.00 | - | |
| Mark James Litton - Officer | Open-market sale | Common Stock | 5,156 | $5.37 | $28K | |
| Mark James Litton - Officer | Option exercise | Restricted Stock Units | 22,254 | $0.00 | - | |
| Robert Renninger - Officer | Option exercise | Restricted Stock Units | 3,900 | $0.00 | - | |
| Robert Renninger - Officer | Option exercise | Common Stock | 3,900 | $0.00 | - | |
| Robert Renninger - Officer | Open-market sale | Common Stock | 906 | $5.37 | $5K | |
| Mark Worthington - Officer | Option exercise | Restricted Stock Units | 5,726 | $0.00 | - | |
| Mark Worthington - Officer | Option exercise | Common Stock | 5,726 | $0.00 | - | |
| Mark Worthington - Officer | Open-market sale | Common Stock | 1,328 | $5.37 | $7K | |
| Kevin Church - Officer | Option exercise | Restricted Stock Units | 5,856 | $0.00 | - | |
| Kevin Church - Officer | Option exercise | Common Stock | 5,856 | $0.00 | - | |
| Kevin Church - Officer | Open-market sale | Common Stock | 1,359 | $5.37 | $7K |
LeonaBio, Inc. (LONA) had 11 insider filings in the last 90 days, with the most recent on 2026-07-10. The full record for LONA runs to 46 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of LONA were filed in the last 90 days.
No insider sales of LONA were filed in the last 90 days. 10 sales are on record for this company.
This page tracks LONA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add LONA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
